It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The mutational mechanisms underlying recurrent deletions in clonal hematopoiesis are not entirely clear. In the current study we inspect the genomic regions around recurrent deletions in myeloid malignancies, and identify microhomology-based signatures in CALR, ASXL1 and SRSF2 loci. We demonstrate that these deletions are the result of double stand break repair by a PARP1 dependent microhomology-mediated end joining (MMEJ) pathway. Importantly, we provide evidence that these recurrent deletions originate in pre-leukemic stem cells. While DNA polymerase theta (POLQ) is considered a key component in MMEJ repair, we provide evidence that pre-leukemic MMEJ (preL-MMEJ) deletions can be generated in POLQ knockout cells. In contrast, aphidicolin (an inhibitor of replicative polymerases and replication) treatment resulted in a significant reduction in preL-MMEJ. Altogether, our data indicate an association between POLQ independent MMEJ and clonal hematopoiesis and elucidate mutational mechanisms involved in the very first steps of leukemia evolution.
The mutational mechanisms that produce insertions and deletions that lead to clonal hematopoiesis are poorly understood. Here the authors show evidence that frequent deletions that are relevant to myeloid malignancies could be produced by PARP1-dependent microhomology-mediated end joining.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Biezuner Tamir 1
; Kaushansky Nathali 1 ; Minden, Mark D 5 ; Gupta, Vikas 6 ; Milyavsky, Michael 7 ; Livneh Zvi 8 ; Tanay Amos 2
; Shlush, Liran I 9
1 Weizmann Institute of Science, Department of Immunology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
2 Weizmann Institute of Science, Department of Computer Science and Applied Mathematics, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
3 University Health Network (UHN), Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
4 University Health Network (UHN), Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
5 University Health Network (UHN), Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Department of Medical Biophysics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University Health Network, Division of Medical Oncology and Hematology, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
6 University Health Network (UHN), Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Department of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University Health Network, Division of Medical Oncology and Hematology, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
7 Tel-Aviv University, Department of Pathology, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Tel-Aviv University, Sackler Faculty of Medicine, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
8 Weizmann Institute of Science, Department of Biomolecular Sciences, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
9 Weizmann Institute of Science, Department of Immunology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563); University Health Network (UHN), Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); Rambam Healthcare Campus, Division of Hematology, Haifa, Israel (GRID:grid.231844.8)




